TLRY

bullish · high conviction track record →

Tilray scales beverage, aims cash flow 2027

Watch: Monitor BrewDog integration completion and UK Hi*Ball Energy launch for impacts on revenue and margins.

Full analysis

Tilray posted Q3 fiscal 2026 revenue of $207M, up 11% YoY and 36% over four years, driven by 117% beverage growth to $42.6M and 18% cannabis growth to $64.8M. It acquired the Lyphe Group to bolster its UK medical platform and launched an ATM equity program for $180M. Insider buying exceeds $158K, signaling confidence despite the stock falling 90% over four years and trading near the low $3.50 range with mixed technicals.

Tilray's diversified revenue growth and strategic acquisitions aim to offset past stock weakness and move the company toward cash-flow positivity by 2027, critical for restoring investor confidence.

Compare

Evidence

14 signals · latest 3h ago

Get alerted when TLRY changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.